CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 535,608	$ 230,276
Marketable securities	158,376	77,819
Accounts receivable - trade, net	787,071	593,207
Accounts receivable from Sanofi	104,707	99,913
Inventories	70,354	28,638
Deferred tax assets	44,677	148,134
Prepaid expenses and other current assets	96,141	28,025
Total current assets	1,796,934	1,206,012
Restricted cash and marketable securities	0	8,186
Marketable securities	389,891	271,230
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	526,983	379,940
Deferred tax assets	231,878	192,022
Other assets	5,327	23,100
Total assets	2,951,013	2,080,490
Current liabilities:
Accounts payable and accrued expenses	250,896	111,345
Deferred revenue from Sanofi, current portion	12,815	17,022
Deferred revenue - other, current portion	34,185	33,809
Facility lease obligations, current portion	939	1,374
Total current liabilities	298,835	163,550
Deferred revenue from Sanofi	76,522	76,520
Deferred revenue - other	107,677	131,822
Facility lease obligations	184,258	159,436
Convertible senior notes	320,315	296,518
Other long term liabilities	11,330	7,259
Total liabilities	998,937	835,105
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	2,045,857	1,763,508
Accumulated deficit	(92,692)	(517,054)
Accumulated other comprehensive loss	(1,188)	(1,166)
Total stockholders' equity	1,952,076	1,245,385
Total liabilities and stockholders' equity	2,951,013	2,080,490
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 97	$ 95